Checked
Alpha Cognition Inc.
Nasdaq: ACOG · Biological Products, (No Diagnostic Substances) · Grapevine, TX
- Revenue
- $10.22M
- Year ended Dec 31, 2025
- Net income
- -$20.67M
- -202.2% net margin
- Total assets
- $79.73M
- Diluted EPS
- -$1.18
Company details
As reported to the SEC
- SEC CIK
- 1655923
- Stock
- Nasdaq: ACOG
- Legal Entity Identifier (LEI)
- 254900J4A8UTBGYKPA90
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 1452 Hughes Rd., Ste. 200, Grapevine, TX 76051
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- Phone
- (858) 344-4375
- Last annual report
- 03/31/2026
- Last quarterly report
- 08/13/2026
Formerly: Neurodyn Cognition Inc. (until 10/09/2019)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 |
|---|---|---|---|
| Revenue | $10.22M | Not reported | Not reported |
| Operating income | -$22.66M | -$12.01M | -$9.94M |
| Net income | -$20.67M | -$14.79M | -$13.76M |
| Diluted earnings per share | -$1.18 | -$2.04 | -$3.84 |
| Research and development | $1.87M | $3.92M | $4.88M |
| Total assets | $79.73M | $50.74M | $2.45M |
| Total liabilities | $17.2M | $11.64M | $7.16M |
| Shareholders' equity | $62.53M | $39.09M | -$4.7M |
| Cash and cash equivalents | $66.05M | $48.55M | $1.4M |
| Cash from operations | -$20.38M | -$7.76M | -$8.8M |
| Capital expenditures | $293.5K | $26.7K | Not reported |
Recent filings
71 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
39 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Alpha Cognition Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Alpha Cognition Inc.'s CIK number?
- Alpha Cognition Inc.'s SEC Central Index Key (CIK) is 1655923.
- What is Alpha Cognition Inc.'s stock ticker?
- Alpha Cognition Inc. trades as Nasdaq: ACOG.
- What was Alpha Cognition Inc.'s revenue?
- Alpha Cognition Inc. reported revenue of $10.22M for the fiscal year ended Dec 31, 2025.
- When does Alpha Cognition Inc.'s fiscal year end?
- Alpha Cognition Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Alpha Cognition Inc. headquartered?
- Alpha Cognition Inc.'s principal executive office on file with the SEC is in Grapevine, TX.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026